title: [Nicorandil: acute hemodynamic effects of 2 different oral doses of a potassium channel opener in patients with coronary heart disease].
abstract: BACKGROUND
  In medical treatment of angina pectoris the 3 major groups of antianginal agents are nitrates, beta blockers and calcium antagonists. Now a new class of drugs is introduced in the therapy: the potassium channel openers. One of the first potassium channel openers is nicorandil. We examined the acute hemodynamic effects of 2 different oral nicorandil doses in patients with coronary heart disease.
  
  
  METHODS
  Twenty patients with angiographic proven coronary heart disease and stable angina pectoris were treated with a dose of 2 x 10 mg Nicorandil on day 1 and 2 x 20 mg Nicorandil on day 2, while being hemodynamically monitored on an intensive care unit with a pulmonary artery catheter.
  
  
  RESULTS
  Through the hemodynamic monitoring a dose dependent, significant reduction of systolic blood pressure was found (6%/9%), while the heart rate increased dose dependently (6%/11%). The rate pressure product as a marker of myocardial oxygen demand did not increase significantly.
  
  
  CONCLUSIONS
  The oral application of nicorandil causes an acute, dose dependent, significant decrease in systolic blood pressure and induces a reflextachycardia.
authors: II. Medizinische Klinik, Universitätsklinik Mainz. christoph.bickel@rz-online.de
authors: C
authors: C
authors: Bickel
authors: H J
authors: HJ
authors: Rupprecht
authors: A
authors: A
authors: Tyrtania
authors: J
authors: J
authors: Rörig
authors: J
authors: J
authors: Meyer
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D015220:Calcium Channels / Q000187:drug effects*; D003326:Coronary Circulation / Q000187:drug effects; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D020108:Nicorandil / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D015220:Calcium Channels; D020108:Nicorandil